European Urology · 2023 · 25 citations · 8 references
MedicineOncologyUrologyDiagnostic ImagingMetastasisMolecular ImagingGenitourinary ImagingGenitourinary Oncology ImagingProstate CancerProstate Cancer ImagingProstate ImagingTumor CharacterizationCastration-resistant Prostate Cancer TherapyGenomic BiomarkersGleason ScoringMetastasis-directed TherapyMetastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate Cancer TherapyProstate Cancer Diagnosis
In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there are multiple definitions of disease volume, they have commonly been studied in the context of metastases detected via conventional imaging (CIM). One such numeric definition of disease volume, termed oligometastasis, is heavily dependent on the sensitivity of the imaging modality. We performed an international multi-institutional retrospective review of men with metachronous oligometastatic CSPC (omCSPC), detected via either advanced molecular imaging alone (AMIM) or CIM. Patients were compared with respect to clinical and genomic features using the Mann-Whitney U test, Pearson’s χ2 test, and Kaplan-Meier overall survival (OS) analyses with a log-rank test. A total of 295 patients were included for analysis. Patients with CIM-omCSPC had significantly higher Gleason grade group (p = 0.032), higher prostate-specific antigen at omCSPC diagnosis (8.0 vs 1.7 ng/ml; p < 0.001), more frequent pathogenic TP53 mutations (28% vs 17%; p = 0.030), and worse 10-yr OS (85% vs 100%; p < 0.001). This is the first report of clinical and biological differences between AMIM-detected and CIM-detected omCSPC. Our findings are particularly important for ongoing and planned clinical trials in omCSPC. Metastatic prostate cancer with just a few metastases only detected via newer scanning methods (called molecular imaging) is associated with fewer high-risk DNA mutations and better survival in comparison to metastatic cancer detected via conventional scan methods.
8
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations
Pharmacy, Oncology, Pharmacotherapy +17
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · JAMA Oncology · 2020 · 1.1K citations · Full text
Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text
Matthew P. Deek, Kim Van der Eecken, Philip Sutera et al. · Journal of Clinical Oncology · 2022 · 243 citations · Full text